Analyst Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies and keeping the price target at $36.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Serge Belanger has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ strong market performance and potential for growth. The company reported impressive sales figures for Yutrepia in the third quarter of 2025, with revenues reaching $51.7 million, a significant increase from the previous quarter and well above market expectations. This robust performance has allowed Liquidia to achieve its first profitable quarter, marking a significant milestone for the company.
Additionally, the rapid adoption of Yutrepia, with over 2,000 unique prescriptions written by more than 600 prescribers, demonstrates strong market acceptance and demand. While there is some uncertainty regarding an upcoming patent litigation decision, the overall outlook remains positive. The anticipated positive market reaction to these results further supports the Buy rating, reflecting confidence in Liquidia’s strategic positioning and future prospects.
In another report released on October 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.